Drug
Gemcitabine-Releasing Intravesical System clinical trials
Also written TAR-200 and JNJ-17000139.
- studies test it
- 9
- open now
- 0
- in phase 3
- 3
- first study started
- 2016
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 2
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Janssen Research & Development, LLC (6) · Taris Biomedical LLC (3)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Gemcitabine-Releasing Intravesical System is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderActive, not recruitingPhase 3Janssen Research & Development, LLCNCT04658862Written as TAR-200
- A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyActive, not recruitingPhase 2Janssen Research & Development, LLCNCT04640623Written as TAR-200
- A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT06211764Written as TAR-200
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT05714202Written as TAR-200
- A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the BladderCompletedPhase 2Janssen Research & Development, LLCNCT04919512Written as TAR-200
- A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical CystectomyCompletedPhase 1Janssen Research & Development, LLCNCT03404791Written as TAR-200
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder CancerTerminatedPhase 1Taris Biomedical LLCNCT03518320Written as Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder CancerCompletedPhase 1Taris Biomedical LLCNCT02722538Written as Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder CancerCompletedPhase 1Taris Biomedical LLCNCT02720367Written as Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200